Works matching DE "PROTEASOME inhibitors"
Results: 1123
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 159, doi. 10.3390/ph18020159
- By:
- Publication type:
- Article
Chemical and Biological Mechanisms Relevant to the Rescue of MG-132-Treated Neurons by Cysteine.
- Published in:
- Antioxidants, 2025, v. 14, n. 2, p. 128, doi. 10.3390/antiox14020128
- By:
- Publication type:
- Article
α-Synuclein Degradation in Brain Pericytes Is Mediated via Akt, ERK, and p38 MAPK Signaling Pathways.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1615, doi. 10.3390/ijms26041615
- By:
- Publication type:
- Article
Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
- Published in:
- Veterinary & Comparative Oncology, 2024, v. 22, n. 1, p. 96, doi. 10.1111/vco.12957
- By:
- Publication type:
- Article
Pre‐clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
- Published in:
- Veterinary & Comparative Oncology, 2018, v. 16, n. 4, p. 544, doi. 10.1111/vco.12413
- By:
- Publication type:
- Article
Development of Potent and Highly Selective Epoxyketone‐Based Plasmodium Proteasome Inhibitors.
- Published in:
- Chemistry - A European Journal, 2023, v. 29, n. 20, p. 1, doi. 10.1002/chem.202203958
- By:
- Publication type:
- Article
Optical Control of Proteasomal Protein Degradation with a Photoswitchable Lipopeptide.
- Published in:
- Angewandte Chemie, 2024, v. 136, n. 8, p. 1, doi. 10.1002/ange.202314791
- By:
- Publication type:
- Article
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti‐malaria Activity in Humanized Mice.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 17, p. 9365, doi. 10.1002/ange.202015845
- By:
- Publication type:
- Article
Light‐Controlled Cell‐Cycle Arrest and Apoptosis.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 3, p. 1207, doi. 10.1002/ange.202008267
- By:
- Publication type:
- Article
Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.
- Published in:
- Angewandte Chemie, 2020, v. 132, n. 38, p. 16587, doi. 10.1002/ange.202006290
- By:
- Publication type:
- Article
Total Synthesis of (−)‐Salinosporamide A via a Late Stage C−H Insertion.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 30, p. 10216, doi. 10.1002/ange.201900340
- By:
- Publication type:
- Article
Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity.
- Published in:
- Histochemistry & Cell Biology, 2012, v. 137, n. 1, p. 25, doi. 10.1007/s00418-011-0869-0
- By:
- Publication type:
- Article
Activities of proteasome and m-calpain are essential for Chikungunya virus replication.
- Published in:
- Virus Genes, 2016, v. 52, n. 5, p. 716, doi. 10.1007/s11262-016-1355-5
- By:
- Publication type:
- Article
Chemical inhibition of the integrated stress response impairs the ubiquitin-proteasome system.
- Published in:
- Communications Biology, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s42003-024-06974-0
- By:
- Publication type:
- Article
蓝光和蛋白酶体抑制剂 MG132 处理对蛹虫草 Cmfrq、Cmwc-1 和 Cmwc-2 转录水平的影响.
- Published in:
- Mycosystema, 2022, v. 41, n. 4, p. 587, doi. 10.13346/j.mycosystema.210352
- By:
- Publication type:
- Article
蓝光和蛋白酶体抑制剂MG132 对蛹虫草形态的 影响.
- Published in:
- Mycosystema, 2021, v. 40, n. 11, p. 2953, doi. 10.13346/j.mycosystema.210160
- By:
- Publication type:
- Article
PEST sequences from a cactus dehydrin regulate its proteolytic degradation.
- Published in:
- PeerJ, 2019, p. 1, doi. 10.7717/peerj.6810
- By:
- Publication type:
- Article
Treating Multiple Myeloma: The Cause for Optimism.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 5, p. 6, doi. 10.1093/jnci/dju140
- By:
- Publication type:
- Article
Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2017, v. 32, n. 1, p. 865, doi. 10.1080/14756366.2017.1334649
- By:
- Publication type:
- Article
Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2016, v. 31, n. 3, p. 456, doi. 10.3109/14756366.2015.1037749
- By:
- Publication type:
- Article
Synthesis and activity of proteasome inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2014, v. 29, n. 1, p. 55, doi. 10.3109/14756366.2012.753590
- By:
- Publication type:
- Article
C-terminal trans, trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2013, v. 28, n. 5, p. 1034, doi. 10.3109/14756366.2012.709241
- By:
- Publication type:
- Article
Impact of High Glucose and Proteasome Inhibitor MG132 on Histone H2A and H2B Ubiquitination in Rat Glomerular Mesangial Cells.
- Published in:
- Journal of Diabetes Research, 2013, p. 1, doi. 10.1155/2013/589474
- By:
- Publication type:
- Article
Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.
- Published in:
- Xenotransplantation, 2013, v. 20, n. 6, p. 429, doi. 10.1111/xen.12052
- By:
- Publication type:
- Article
Mini-Orals 1 & 2.
- Published in:
- Xenotransplantation, 2013, v. 20, n. 5, p. 330, doi. 10.1111/xen.12060_10
- Publication type:
- Article
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01197-2
- By:
- Publication type:
- Article
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01182-9
- By:
- Publication type:
- Article
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00946-z
- By:
- Publication type:
- Article
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00957-w
- By:
- Publication type:
- Article
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00912-9
- By:
- Publication type:
- Article
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00768-5
- By:
- Publication type:
- Article
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00626-4
- By:
- Publication type:
- Article
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00507-2
- By:
- Publication type:
- Article
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 12, p. 1, doi. 10.1038/s41408-020-00393-0
- By:
- Publication type:
- Article
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.
- Published in:
- 2020
- By:
- Publication type:
- Letter to the Editor
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Oprozomib in patients with newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0232-6
- By:
- Publication type:
- Article
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.
- Published in:
- 2019
- By:
- Publication type:
- Letter
A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-78350-1
- By:
- Publication type:
- Article
miR-326 overexpression inhibits colorectal cancer cell growth and proteasome activity by targeting PNO1: unveiling a novel therapeutic intervention strategy.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-75746-x
- By:
- Publication type:
- Article
miR-326 overexpression inhibits colorectal cancer cell growth and proteasome activity by targeting PNO1: unveiling a novel therapeutic intervention strategy.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-75746-x
- By:
- Publication type:
- Article
Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-70296-8
- By:
- Publication type:
- Article
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-69465-6
- By:
- Publication type:
- Article
Nocardia farcinica Brain Abscess in a Multiple Myeloma Patient Treated with Proteasome Inhibitor: A Case Report and Review of the Literature.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 1, p. 76, doi. 10.3390/biom15010076
- By:
- Publication type:
- Article
Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 12, p. 1777, doi. 10.3390/biom12121777
- By:
- Publication type:
- Article
The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 8, p. 1150, doi. 10.3390/biom12081150
- By:
- Publication type:
- Article
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 6, p. 756, doi. 10.3390/biom12060756
- By:
- Publication type:
- Article
Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 2, p. 315, doi. 10.3390/biom12020315
- By:
- Publication type:
- Article